ImmunoPrecise Antibodies Ltd. (IPA)

ImmunoPrecise Antibodies Stock Forecast

IPA's stock price has decreased by -75% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts with 12-month price forecasts for IPA stock have an average target of 6.00, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 1,295.35% from the current stock price of 0.43.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$6.00	$9.00	$9.00
Change	+597.67%	+1295.3%	+1993.0%	+1993.0%

* Price targets were last updated on Sep 17, 2024.

Analyst Ratings

The average analyst rating for IPA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	May '24	Jun '24	Jul '24	Aug '24	Sep '24	Oct '24
Strong Buy	1	1	1	1	1	1
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $9	Strong Buy	Reiterates	$9	+1,993.02%	Sep 17, 2024
Robert Wasserman Benchmark	Benchmark	Buy Maintains $5 → $3	Buy	Maintains	$5 → $3	+597.67%	Aug 14, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $9	Strong Buy	Reiterates	$9	+1,993.02%	Jul 30, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $9	Strong Buy	Reiterates	$9	+1,993.02%	Mar 15, 2024
Robert Wasserman Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+1,062.79%	Mar 15, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

25.58M

Increased by 4.33%

from 24.52M

Revenue Next Year

34.70M

Increased by 35.64%

from 25.58M

EPS This Year

-0.47

from -1.06

EPS Next Year

-0.22

from -0.47

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Apr 30, 2020	Apr 30, 2021	Apr 30, 2022	Apr 30, 2023	Apr 30, 2024	Apr 30, 2025	Apr 30, 2026	Apr 30, 2027
Revenue	14.06M	17.91M	19.36M	20.67M	24.52M	25.58M	34.70M	42.02M
Revenue Growth	28.66%	27.41%	8.11%	6.72%	18.65%	4.33%	35.64%	21.09%
EPS	-0.36	-0.45	-0.85	-1.07	-1.06	-0.47	-0.22	-0.02
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	2	2

Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	28.0M	36.1M	43.7M
Avg	25.6M	34.7M	42.0M
Low	23.5M	33.7M	40.8M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	14.1%	41.0%	25.9%
Avg	4.3%	35.6%	21.1%
Low	-4.0%	31.6%	17.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.42	-0.23	-0.02
Avg	-0.47	-0.22	-0.02
Low	-0.52	-0.22	-0.02

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.